Samuelson TW, Singh IP, Williamson BK, Falvey H, Lee WC, Odom D, McSorley D, Katz LJ. Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® Pivotal Trial. Am J Ophthalmol. 2021 Mar 15;229:220-9. doi: 10.1016/j.ajo.2021.03.007
Samuelson T, Singh IP, Katz LJ, Falvey H, Odom D, McSorley D. Effect of iStent inject trabecular micro-bypass on patient-reported outcomes for those with open-angle glaucoma and coexisting cataracts. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Odom D, McLeod L, Sherif B, Nelson L, McSorley D. Longitudinal modeling approaches to assess the association between changes in 2 clinical outcome assessments. Ther Innov Regul Sci. 2018 May;52(3):306-12. doi: 10.1177/2168479017731584
Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2004;99:1-9.
Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Most bothersome symptoms in irritable bowel syndrome (IBS) patients. Am J Gastroenterol. 2004;99(10):842.
Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Correlating global outcome measures in Irritable Bowel Syndrome (IBS). Am J Gastroenterol. 2004;99(10):843.
Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol. 2001 Mar;96(3):803-11.
Watson ME, Lacey LA, McSorley DJ, Kong NS, Northcutt AR, Mangel AW. Patient satisfaction with alosetron for the treatment of irritable bowel syndrome (IBS). Poster presented at the Digestive Disease Week and the 101st Annual Meeting of the American Gastroenterological Association; May 2000. [abstract] Gastroenterology. 2000 Apr; 118((4) Part 1):A219.
Vakil N, Hahn B, McSorley DJ. Recurrent symptoms and gastro-oesophageal reflux disease in patient with duodenal ulcer treated for helicobacter pylori infection. Aliment Pharmacol Ther. 2000 Jan;14(1):45-51.
Camilleri M, Mayer EA, Drossman DA, Heath AT, Dukes GE, McSorley DJ, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.
Schwartz HI, Perschy TB, McSorley DJ, Sorrells SC. Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Am J Gastroenterol. 1999 Jun;4(2):121-7.
Vakil N, McSorley DJ, Hahn BA. Clarithromycin-resistant helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998 Sep;93(9):1432-5.
Lanza FL, Sontag SJ, Ciociola AA, Sykes DL, Heath AT, McSorley DJ. Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. Helicobacter. 1998 Sep;3(3):212-21.
Graham DY, Breiter JR, Ciociola AA, Sykes DL, McSorley DJ. An alternative non-macrolide, non-imidazole treatment for curing helicobacter pylori and duodenal ulcers: ranitidine bismuth citrate plus amoxicillin. Helicobacter. 1998 Jun;3(2):125-31.
Northcutt AR, Camilleri M, Mayer EA, Dossman DA, Dukes GE, Ehsanullah RSB, McSorley DJ. Alosetron, a 5-HT3-receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterology. 1998;114:A812.
Vakil N, McSorley DJ. Reflux symptoms after h. pylori treatment in duodenal ulcer. Poster presented at the British Society of Gastroenterology Diamond Jubilee Meeting; March 1997. [abstract] Gut. 1997 Jan; 40(Suppl 1):A128.
Vakil N, McSorley DJ. The incremental cost and utility of cultures for helicobacter pylori. Gastroenterology. 1997;112(4):A319.
Perschy TB, McSorley DJ. Ranitidine bismuth citrate in combination with clarithromycin is effective against h. pylori strains with susceptible or intermediate clarithromycin sensitivity. Gastroenterology. 1997;112(4):A257.
Ciociola AA, Webb DD, McSorley DJ. The continued use of placebo-controlled clinical trials in the study of peptic ulcer disease: a sponsor perspective. Drug Inf J. 1996 Apr;30(2):433-9.
Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate (tritec) plus clarithromycin is effective for healing duodenal ulcers, eradicating h.pylori, and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10(3):251-61.
Ciociola AA, McSorley DJ. Consistent criteria should be employed in calculating h. pylori (HP) eradication rates: application of different published study criteria to ranitidine bismuth citrate (RBC) clinical trial data. Am J Gastroenterol. 1996;91(9):1907.
Moore JG, Coburn JW, Sanders MC, McSorley DJ, Sirgo MA. Effects of sucralfate and ranitidine on aluminum concentrations in elderly volunteers. Pharmacotherapy. 1995 Dec;15(6):742-6.
Peterson WL, Sontag SJ, Ciociola AA, Sykes DL, McSorley DJ, Webb DD, the H. pylori Ulcer Group. Ranitidine bismuth citrate plus clarithromycin is effective in the eradication of helicobacter pylori and prevention of duodenal ulcer relapse. Poster presented at the Digestive Disease Week and the 95th Annual Meeting of the American Gastroenterological Association; May 1995. [abstract] Gastroenterology. 1995 Apr; 108(4 (Suppl 1)):A190. doi: 10.1016/0016-5085(95)23422-5
Graham DY, Hirshowitz B, Ciociola AA, Sykes DL, McSorley DJ. Ranitidine bismuth citrate plus amoxicillin for the treatment of duodenal ulcer disease. Am J Gastroenterol. 1995;90(9):638.
Koch GG, Amara LA, Forster JK, McSorley DJ, Peace KE. Statistical issues in the design and analysis of ulcer healing and recurrence studies. Drug Inf J. 1993 Jul;27(3):805-24.
Johnson JA, Euler AR, Northcutt AR, McSorley DJ. Ranitidine 300mg at bedtime is effective for gastric ulcers: a 12-week, multicenter, randomized, double-blind, placebo-controlled comparison. Am J Gastroenterol. 1993;88(7):1071-5.
Marshall B, Ciociola AA, McSorley DJ, Webb DD. Computerized phone-in symptom recording system correlates with patient recorded symptom diary card for patients with non-ulcer dyspepsia. Am J Gastroenterol. 1993;91(9):1992.
Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of chronic oral dosing of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory activity. Gastroenterology. 1992;102(4):A50.
Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of ascending oral doses of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory properties. Gastroenterology. 1992;102(4):A51.
Euler AR, Johnson JA, Dawson D, Kleoudis C, McSorley DJ. A comparison of ranitidine 150mg and placebo administered at bedtime for maintenance of recurrent benign gastric ulcers. Am J Gastroenterol. 1992;87(9):1267.